KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) FCF Margin (2016 - 2025)

Historic FCF Margin for Xenon Pharmaceuticals (XENE) over the last 11 years, with Q1 2025 value amounting to 822.6%.

  • Xenon Pharmaceuticals' FCF Margin changed N/A to 822.6% in Q1 2025 from the same period last year, while for Sep 2025 it was 3377.15%, marking a year-over-year change of. This contributed to the annual value of 1101.57% for FY2022, which is 7134800.0% down from last year.
  • As of Q1 2025, Xenon Pharmaceuticals' FCF Margin stood at 822.6%.
  • Xenon Pharmaceuticals' FCF Margin's 5-year high stood at 212.64% during Q1 2022, with a 5-year trough of 23324.24% in Q3 2022.
  • Its 3-year average for FCF Margin is 3703.67%, with a median of 599.26% in 2021.
  • The largest annual percentage gain for Xenon Pharmaceuticals' FCF Margin in the last 5 years was 2718000bps (2022), contrasted with its biggest fall of -229858000bps (2022).
  • Quarter analysis of 3 years shows Xenon Pharmaceuticals' FCF Margin stood at 567.94% in 2021, then tumbled by -4007bps to 23324.24% in 2022, then surged by 96bps to 822.6% in 2025.
  • Its last three reported values are 822.6% in Q1 2025, 23324.24% for Q3 2022, and 3248.51% during Q2 2022.